Navigation Links
InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
Date:8/6/2009

----------- Initiate ritonavir boosting MAD study in HCV Patients Q3 2009 -------------------------------------------- ------- INFORM-1 presentations at AASLD: Results of all cohorts, PK/PD profile and viral resistance profile November 3, 2009 ----------------------------------------------- ---------------- Rapid Virologic Response (RVR) data from Phase 2b (12-week regimen) Q1 2010 ------------------------------------------------- -------

Other Recent Business Highlights

InterMune expanded its leadership team in support of the anticipated commercialization of pirfenidone and named Barrett McGrath to the newly created position of Vice President of Sales and Marketing. Mr. McGrath has nearly 30 years of experience in the industry, having held leadership positions in sales, marketing and business development at Genentech, DuPont Pharmaceuticals, American Hospital Supply Corporation (now Baxter) and Quintiles Transnational. As a consultant, he has led InterMune's pirfenidone pre-launch team since the spring of 2008.

Guidance for 2009 Revenue and Expenses

The company reiterated its 2009 financial guidance for revenue and operating expenses, which is unchanged from the guidance initially provided on February 26, 2009.

Revenue: 2009 revenue, including Actimmune(R) and anticipated milestone payments from Roche, is expected to be in a range of approximately $40 to $50 million. Actimmune revenue represents approximately 50 percent of this revenue range. The guidance includes an expected $20 million milestone payment from Roche upon initiation of the Phase 2b study of ITMN-191, expected in August.

Operating Exp
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. InterMune to Release Second Quarter Financial Results on August 6
2. InterMune to Present at Goldman Sachs Healthcare Conference
3. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
4. InterMune to Release First Quarter Financial Results on April 30
5. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
6. InterMune to Present at Canaccord Adams Hepatitis C Conference
7. InterMune to Present at Citis 4th Annual Biotech Day
8. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
9. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
10. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
11. InterMune Announces Issuance of U.S. Patent for ITMN-191
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Pittcon Organizing Committee is pleased to ... Tech , an e-Journal and producer of Food ... second year for the co-location of Food Labs Conference to ... that the registration fee to attend the two-day Food Lab ...
(Date:1/15/2014)... 15, 2014 Look inside the new ... for the lab, from fluid handling to instruments to ... ship when you order. , Preferred Solutions features ... from the L/S® model for precise flow control and ...
(Date:1/15/2014)... and SAN JOSE, California , ... biotechnology company developing antibody-drug conjugates for cancer, today announced the ... of Directors. Dr Reynolds has over 20 years, development experience ... Officer at Seattle Genetics. "I am delighted to ...
(Date:1/15/2014)... This webinar will focus on EMA and ... in biosimilars. , Regulatory frameworks are evolving many countries ... the complex nature of biopharmaceuticals makes the demonstration of ... challenging. Based on the specific aspects of biosimilar drug ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2
... Underscores Morphotek,s Commitment to the Development of Farletuzumab ... Specialty Development and Manufacturing SolutionsEXTON, Pa. and BASEL, ... of Eisai Corporation of North America, and Lonza ... executed a manufacturing services agreement to support the ...
... and biotech,companies are drawing on Singapore,s integrated network ... productivity, leverage academic,insights and diversify risks. Located at ... is representative of key Asian ethnic groups, Singapore ... and develop new solutions for,Asia and beyond. , ...
... signed an agreement-in-principle to ensure the valorization and the operation ... the Faculty of veterinary medicine in St-Hyacinthe, Quebec, Canada, for ... ... Laval, Quebec (PRWEB) May 18, 2009 -- Universite de ...
Cached Biology Technology:Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement 2Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement 3Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement 4Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 2Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 3Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 4Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 5
(Date:4/17/2014)... in bone marrow need to produce hydrogen sulfide in ... to a new study from the Center for Craniofacial ... of USC. , Professor Songtao Shi, principal investigator on ... by the cells governs the flow of calcium ions. ... that results in osteogenesis, or the creation of new ...
(Date:4/17/2014)... Singh Thursday as a "Champion of Change" for ... in the residential, commercial and industrial sectors. , ... and Computer Engineering and director of Clemson,s Center ... leading the charge across the country to create ... driving policy changes at the local level to ...
(Date:4/17/2014)... honeybees in Europe, Asia and the United States are ... be impacting native honeybee populations at this time, according ... include including Nosema microsporidia and Varroa ... resilient to these invasive pests, which suggests to us ... Asia and the United States currently are not necessary ...
Breaking Biology News(10 mins):White House honors Clemson professor as 'Champion of Change' for solar deployment 2East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3
... This release is available in French . ... can stunt growth and foster weight gain during puberty, ... Journal of Clinical Endocrinology & Metabolism . Even in ... Centre (MUHC) and the University of Southern California conducted ...
... Fluorescent molecules i.e. substances which can be stimulated ... biological research and medical diagnosis. Fluorescence can be used ... genes, to locate proteins in cells and tissues, to ... migration of cells. Of particular importance is the combination ...
... chemical additives and refined sweeteners in commercial salad dressings, ... capitalize on the positive health effects of honey, we ... Engeseth, a U of I associate professor of food ... the quality of the salad dressings for up to ...
Cached Biology News:Lack of vitamin D causes weight gain and stunts growth in girls 2Novel technique for fluorescence tomography of tumors in living animals 2Honey adds health benefits, is natural preservative and sweetener in salad dressings 2
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 50 ug...
Dog polyclonal to Porcine Pancreatic Islets of Langerhans Cells ( Abpromise for all tested applications). Antigen: Tissue / cell preparation (Pig): Sonicated crude membrane fraction of porcine p...
Anti-human C5/C5b, Clone 568, Monoclonal Antibody...
Biology Products: